Business
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming commitment to advancing in
About this update from Addex Therapeutics Ltd
[{"type":"image","alt":"Addex Therapeutics","displaySize":"","headline":null,"caption":"Addex Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":231,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/1f8146359a7fe2dec0ebef0293b159e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i1_J.LrQ5M.Eo1NBP2WLjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1f8146359a7fe2dec0ebef0293b159e7","width":231,"height":115}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash position of CHF 2.3 million at end of H1 2025","length":50,"tagName":"p"}]},{"val":[{"type":"text","content":"GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models ","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Regained rights to phase 2 mGlu2 PAM asset, ADX71149","length":52,"tagName":"p"}]},{"val":[{"type":"text","content":"Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Entered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Invested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders","length":99,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":536,"olType":false},{"type":"text","content":"Ad Hoc Announcement Pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"Geneva, Switzerland, September 30, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2025, and provided a corporate update.","length":371,"tagName":"p"},{"type":"text","content":"“We have seen great progress in the first six months of 2025, both in terms of drug candidate development and achieving business milestones. In particular, progress continues well and on track with our GABAB PAM drug candidate in chronic cough. We also presented positive data from the cough program,...